Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.37), $0.06 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $19.8 million versus the consensus estimate of $38.68 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.